Inicio › Trastorno depresivo mayor › Washington
Ensayos clínicos de Trastorno depresivo mayor en Washington
20 estudios sobre Trastorno depresivo mayor buscan participantes en Washington.
Ciudades en Washington
Texto oficial del estudio (inglés)
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Core Clinical Research, Everett
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 25 sept 2026 · NCT06559306A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Core Clinical Research, Everett
- Seattle Neuropsychiatric Treatment Center, Seattle
ReclutandoFase 3
Edades de 18 a 85 · Todos los sexos · Actualizado el 25 sept 2026 · NCT06793397Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Northwest Clinical Research Center, Bellevue
ReclutandoFase 3
Edades de 18 a 65 · Todos los sexos · Actualizado el 25 sept 2026 · NCT05850689Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Bellevue
ReclutandoFase 3
Edades de 18 a 65 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06830044A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Everett
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 14 sept 2026 · NCT07065240A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Bellevue
- Draig Clinical Site, Seattle
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT07610473A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Northwest Clinical Research Center, Bellevue
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 28 ago 2026 · NCT07573176A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Bellevue
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 26 ago 2026 · NCT07300969Positive Processes and Transition to Health (PATH)
- University of Washington, Seattle
Reclutando
Edades de 18 a 65 · Todos los sexos · Actualizado el 19 ago 2026 · NCT06093906Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 14 ago 2026 · NCT07226232A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Seattle Neuropsychiatric Treatment Center, Seattle
- VA Portland Healthcare System, Vancouver
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 10 ago 2026 · NCT07592689A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Northwest Clinical Research Center, Bellevue
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 6 ago 2026 · NCT07412756A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Core Clinical Research, Everett
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 3 ago 2026 · NCT06775379Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Everett
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 jul 2026 · NCT06966401A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Northwest Clinical Research Center /ID# 277484, Bellevue
- Core Clinical Research /ID# 277518, Everett
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 15 jun 2026 · NCT07276997A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Seattle Neuropsychiatric Treatment Center, Bellevue
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 11 may 2026 · NCT06524830Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #143, Bellevue
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 20 ene 2026 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Everett
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2025 · NCT06786624A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Everett
ReclutandoFase 4
Edades de 18 a 65 · Todos los sexos · Actualizado el 23 ene 2025 · NCT06223880InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
- University of Washington Medical Center, Seattle
Reclutando
Edades de 18 a 64 · Todos los sexos · Actualizado el 19 sept 2024 · NCT06005194De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.